Blueprint Medicines (NASDAQ:BPMC) Receives Buy Rating from Cowen
Cowen reissued their buy rating on shares of Blueprint Medicines (NASDAQ:BPMC) in a research note released on Monday morning, AnalystRatings.com reports.
A number of other equities analysts have also recently weighed in on BPMC. BidaskClub cut Blueprint Medicines from a hold rating to a sell rating in a report on Thursday, August 22nd. Raymond James reissued a market perform rating on shares of Blueprint Medicines in a report on Wednesday, August 14th. ValuEngine raised Blueprint Medicines from a buy rating to a strong-buy rating in a report on Tuesday, June 4th. Canaccord Genuity raised their price objective on Blueprint Medicines from $105.00 to $120.00 and gave the company a buy rating in a report on Friday, August 2nd. Finally, Piper Jaffray Companies assumed coverage on Blueprint Medicines in a report on Thursday, August 29th. They set a neutral rating and a $85.00 price objective on the stock. Two analysts have rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Blueprint Medicines currently has an average rating of Buy and a consensus price target of $107.60.
Shares of NASDAQ:BPMC traded up $0.07 on Monday, hitting $76.89. The company’s stock had a trading volume of 27,518 shares, compared to its average volume of 461,936. The company has a 50-day simple moving average of $84.83 and a 200 day simple moving average of $84.70. Blueprint Medicines has a 1 year low of $44.58 and a 1 year high of $102.98. The company has a market capitalization of $3.59 billion, a PE ratio of -14.26 and a beta of 1.64. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.52 and a quick ratio of 7.52.
In related news, Director George Demetri sold 1,136 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $98.50, for a total transaction of $111,896.00. Following the transaction, the director now directly owns 5,303 shares in the company, valued at approximately $522,345.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Anthony L. Boral sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $80.07, for a total value of $800,700.00. Following the transaction, the insider now owns 1,300 shares in the company, valued at $104,091. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 106,155 shares of company stock worth $9,511,402. 4.02% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of BPMC. Rockefeller Capital Management L.P. grew its position in Blueprint Medicines by 4,594.1% during the 2nd quarter. Rockefeller Capital Management L.P. now owns 798 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 781 shares during the last quarter. Whittier Trust Co. bought a new position in Blueprint Medicines during the 2nd quarter worth approximately $97,000. Ladenburg Thalmann Financial Services Inc. grew its position in Blueprint Medicines by 62.8% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,097 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 423 shares during the last quarter. Trexquant Investment LP bought a new position in Blueprint Medicines during the 2nd quarter worth approximately $203,000. Finally, Flinton Capital Management LLC bought a new position in Blueprint Medicines during the 2nd quarter worth approximately $211,000.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Read More: CBOE Russell 2000® Volatility Index
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.